Importance Acute coronary syndrome (ACS) is a major cause of morbidity and mortality in
the United States with an annual incidence of approximately 1 million. Dual antiplatelet …

Introduction In patients with acute coronary syndromes (ACS) undergoing percutaneous
coronary intervention (PCI), dual antiplatelet therapy (DAPT) with a potent P2Y12 inhibitor is …

Objectives This study assessed the ability of the dual-antiplatelet therapy (DAPT) score in
stratifying ischemic and bleeding risk in a contemporary percutaneous coronary intervention …

Background: Longitudinal bleeding risk scores have been validated in patients treated with
dual antiplatelet therapy (DAPT) following percutaneous coronary intervention. How these …

Background Very short (≤ 3 months) duration of dual antiplatelet therapy (VSDAPT) has
recently been proposed after percutaneous coronary intervention (PCI) with drug-eluting …

Percutaneous coronary intervention (PCI) with stenting for the treatment of acute coronary
syndrome (ACS) is the contemporary standard of care. Such treatment is followed by dual …

Abstract Background The recent American Heart Association/American College of
Cardiology guidelines on duration of dual antiplatelet therapy (DAPT) recommend DAPT for …

Inhibition of platelet function by means of dual antiplatelet therapy (DAPT) is the cornerstone
of treatment of acute coronary syndrome (ACS). While preventing ischemic recurrences …

Background While extended dual antiplatelet therapy (DAPT) with aspirin and a platelet
(P2Y 12) inhibitor after percutaneous coronary intervention (PCI) reduces the risk of stent …

Abstract Background The PRECISE-DAPT and PARIS risk scores (RSs) were recently
developed to help clinicians at individualizing the optimal dual antiplatelet therapy duration …